Big biotech Gilead Sciences (GILD) soundly beat analysts’ Q3 expectations and raised its guidance yet again Tuesday, though the stock slipped about 1% in after-hours trading. Gilead’s earnings, excluding one-time items, jumped 75% over the year-earlier quarter to $3.22 a share, beating analysts’ consensus by 35 cents, according to Thomson Reuters. Revenue climbed 37% to $8.3 billion, topping Wall Street’s average estimate by nearly $500 million.
Microsoft delivered a big earnings beat for the September quarter, sending its stock to a more-than-15-year high in after-hours trading Thursday. Microsoft (MSFT) earned 67 cents a share excluding items on adjusted sales of $21.66 billion in its fiscal first quarter of 2016. Analysts polled by Thomson Reuters expected Microsoft to earn 59 cents a share on sales of $21.03 billion for the quarter, which ended Sept. 30. On a year-over-year basis, EPS
The FDA said Thursday that it’s requiring that a warning of liver damage be put on the labels of AbbVie’s (ABBV) hepatitis C treatments Viekira Pak and Technivie, sending AbbVie shares plunging to an 18-month low and those of Gilead Sciences (GILD) up sharply. “Our review of adverse events reported to the FDA Adverse Event Reporting System (FAERS) database and to the manufacturer of these medicines, AbbVie, identified cases of hepatic